Business Context and Reporting Period
Company: ImmuCell Corporation (ICCC)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: ImmuCell is an animal health biologics company focused on neonatal calf health, primarily through its First Defense product line which prevents calf scours using hyperimmunized bovine colostrum. The company operates two reportable segments: Scours (First Defense) and Mastitis (Re-Tain and CMT). In December 2025, management announced a strategic pivot to focus exclusively on the Scours market, pausing further investment in the Re-Tain manufacturing initiative.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Product Sales | $27.64 million | $26.49 million |
| Gross Profit | $11.45 million | $7.94 million |
| Gross Margin | 41.4% | 30.0% |
| Net Operating Income (Loss) | $1.65 million | ($1.64 million) |
| Net Loss | ($1.04 million) | ($2.16 million) |
| Cash and Cash Equivalents | $3.81 million | $3.76 million |
| Total Debt (Net) | $9.10 million | $10.50 million |
| Operating Cash Flow | $2.48 million | $0.36 million |
Material Changes vs. Prior Period
- Revenue Growth: Product sales increased 4.3% year-over-year, driven by a $4.2 million increase in Tri-Shield sales, partially offset by a migration from Dual-Force products.
- Margin Expansion: Gross margin improved significantly from 30% to 41.4%. This was achieved through manufacturing efficiencies and volume growth, despite a $0.7 million inventory write-down.
- Profitability Turnaround: The company swung from a net operating loss of $1.64 million in 2024 to a net operating income of $1.65 million in 2025.
- Strategic Pivot & Impairment: Due to FDA regulatory delays with the Re-Tain product, the company ceased investment in Re-Tain manufacturing. This resulted in a $2.67 million non-cash impairment charge on property, plant, and equipment.
- Administrative Costs: Administrative expenses rose 44% to $3.2 million, primarily due to $0.8 million in costs associated with executive leadership changes (new CEO and CFO).
- Backlog Resolution: The company eliminated a significant order backlog that existed in 2024, ending 2025 with no material backlog.
Guidance, Outlook, and Risks
Outlook and Strategy:
- Focus on First Defense: Management plans to redeploy Re-Tain assets to expand First Defense manufacturing capacity. The strategy includes increasing U.S. market share, entering new international markets, and innovating product formats.
- Capacity Expansion: Manufacturing capacity grew to 4.6 million units in 2025. Future plans involve further capacity increases to meet demand.
- Liquidity: Management believes existing cash, operating cash flows, and a $1.0 million line of credit (extended to September 2026) are sufficient to fund operations for at least the next 12 months.
Risks and Contingencies:
- Debt Covenants: The company must maintain a minimum Debt Service Coverage (DSC) ratio of 1.35. The 2025 ratio was 2.65, but the 2024 ratio was 0.73 (waived by lenders). Future compliance is not guaranteed.
- Customer Concentration: Two distributors accounted for 72% of total sales and 69% of trade accounts receivable in 2025.
- Supply Chain: Reliance on a single manufacturing location in Portland, Maine, and specific farms for colostrum collection creates business interruption risks.
- Regulatory: Continued reliance on USDA approvals for First Defense and the uncertainty of licensing Re-Tain to third parties.
Investor Verification Checklist
- Debt Covenant Compliance: Verify the company's ability to maintain the 1.35 DSC ratio in 2026 without requiring lender waivers.
- Re-Tain Asset Utilization: Monitor the timeline and cost efficiency of refitting Re-Tain facilities for First Defense production to ensure the $2.7 million impairment does not lead to further write-downs.
- Customer Concentration: Assess the financial health and contract stability of the two distributors representing 72% of revenue.
- Executive Retention: Confirm the retention of the new CEO and CFO and the integration of their strategic plans.
- Inventory Valuation: Review the $9.27 million inventory balance, specifically the $3.4 million in colostrum, for potential future write-downs given biological yield variability.